Eli Lilly says obesity-drug combination improved weight loss in mid-stage trial
Eli Lilly said a combination of its amylin drug eloralintide and tirzepatide increased weight loss in a mid-stage obesity trial. The company said it plans to begin Phase 3 testing of the regimen at the end of the year, moving the combination toward a later stage of clinical development.
Eli Lilly said a combination regimen pairing its amylin drug eloralintide with tirzepatide improved weight loss in a mid-stage trial. The company’s announcement concerned the potential use of the two drugs together in treating obesity.
The report did not provide the trial’s weight-loss figures, participant details, safety findings or duration. It also did not specify how the combination performed against tirzepatide alone or another comparison group.
Lilly said it plans to start Phase 3 trials of the combination at the end of the year. Phase 3 testing would represent a later stage of clinical evaluation for the regimen.
THE QUESTIONS THIS EVENT LEAVES BEHIND
What weight-loss results did the combination produce compared with tirzepatide alone?
Which safety findings will determine whether the regimen advances through Phase 3 testing?
How might access to a combination treatment be affected by its eventual price?
What patient characteristics could influence the regimen’s effectiveness?
What evidence would be needed before the combination could be considered for broad use?
YOUR QUESTION
Does this story leave you with another question?
Send us the question the report did not answer. It may become the next question IAQ investigates.
GLOBAL CURIOSITY MAP · SEPTEMBER 2026